Novel insight into the agonistic mechanism of alefacept in vivo

Differentially expressed genes may serve as biomarkers of response in psoriasis patients

Asifa S. Haider, Michelle A. Lowes, Humphrey Gardner, Raj Bandaru, Kamruz Darabi, Francesca Chamian, Toyoko Kikuchi, Patricia Gilleaudeau, Mary S. Whalen, Irma Cardinale, Inna Novitskaya, James G. Krueger

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Alefacept is an LFA3-Ig fusion protein that binds to CD2 and is thought to inhibit T cell activation by antagonism of CD2 signaling or by lysis of CD2 + cells. Alefacept is potential future therapeutic for organ transplant recipients or graft-vs-host disease and is an approved therapeutic for psoriasis vulgaris, which is a T cell-mediated inflammatory disease. However, alefacept improves psoriasis in only ∼50% of patients treated for 12 wk. We studied the immunologic effects of alefacept in a group of psoriasis patients during treatment. We found that T cells, especially CD8+ T cells, were rapidly decreased in the peripheral circulation. Decreases in circulating T cells were not associated with induced apoptosis. Unexpectedly, in addition to suppression of inflammatory genes, we found a marked induction of mRNAs for STAT1, IL-8, and monokine induced by IFN-γ during the first day of treatment in PBMC. We confirmed the agonistic effects of alefacept in PBMC in vitro, which were similar to CD3/CD28 ligation on T cells. These data establish that alefacept activates gene expression programs in leukocytes and suggest that its therapeutic action may be as a mixed agonist/antagonist. Furthermore, responding patients to alefacept treatment show unique patterns of gene modulation. Whereas alefacept down-regulated TCRs CD3D and CD2 in responders, nonresponders reveal a higher expression of T cell activation genes such as CD69 in pretreatment PBMC. These finding suggest a potential basis for categorizing responders vs nonresponders at an early time point in treatment or before treatment of a broad range of proinflammatory diseases. This study 1) establishes alefacept as a novel CD2 agonist molecule for induction of leukocyte activation genes (prior work proposed its mechanism as a CD2 antagonist) and 2) that differential activation of genes may categorize clinical responders to this agent, critical for cost-effective use of this drug.

Original languageEnglish (US)
Pages (from-to)7442-7449
Number of pages8
JournalJournal of Immunology
Volume178
Issue number11
StatePublished - Jun 1 2007
Externally publishedYes

Fingerprint

Psoriasis
Biomarkers
T-Lymphocytes
Genes
Transcriptional Activation
Therapeutics
Leukocytes
Monokines
Transplants
alefacept
Graft vs Host Disease
Interleukin-8
Ligation
Apoptosis
Gene Expression
Costs and Cost Analysis
Messenger RNA
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology

Cite this

Haider, A. S., Lowes, M. A., Gardner, H., Bandaru, R., Darabi, K., Chamian, F., ... Krueger, J. G. (2007). Novel insight into the agonistic mechanism of alefacept in vivo: Differentially expressed genes may serve as biomarkers of response in psoriasis patients. Journal of Immunology, 178(11), 7442-7449.

Novel insight into the agonistic mechanism of alefacept in vivo : Differentially expressed genes may serve as biomarkers of response in psoriasis patients. / Haider, Asifa S.; Lowes, Michelle A.; Gardner, Humphrey; Bandaru, Raj; Darabi, Kamruz; Chamian, Francesca; Kikuchi, Toyoko; Gilleaudeau, Patricia; Whalen, Mary S.; Cardinale, Irma; Novitskaya, Inna; Krueger, James G.

In: Journal of Immunology, Vol. 178, No. 11, 01.06.2007, p. 7442-7449.

Research output: Contribution to journalArticle

Haider, AS, Lowes, MA, Gardner, H, Bandaru, R, Darabi, K, Chamian, F, Kikuchi, T, Gilleaudeau, P, Whalen, MS, Cardinale, I, Novitskaya, I & Krueger, JG 2007, 'Novel insight into the agonistic mechanism of alefacept in vivo: Differentially expressed genes may serve as biomarkers of response in psoriasis patients', Journal of Immunology, vol. 178, no. 11, pp. 7442-7449.
Haider, Asifa S. ; Lowes, Michelle A. ; Gardner, Humphrey ; Bandaru, Raj ; Darabi, Kamruz ; Chamian, Francesca ; Kikuchi, Toyoko ; Gilleaudeau, Patricia ; Whalen, Mary S. ; Cardinale, Irma ; Novitskaya, Inna ; Krueger, James G. / Novel insight into the agonistic mechanism of alefacept in vivo : Differentially expressed genes may serve as biomarkers of response in psoriasis patients. In: Journal of Immunology. 2007 ; Vol. 178, No. 11. pp. 7442-7449.
@article{a4e2a2e6ecb944689b85cbd18ff5e382,
title = "Novel insight into the agonistic mechanism of alefacept in vivo: Differentially expressed genes may serve as biomarkers of response in psoriasis patients",
abstract = "Alefacept is an LFA3-Ig fusion protein that binds to CD2 and is thought to inhibit T cell activation by antagonism of CD2 signaling or by lysis of CD2 + cells. Alefacept is potential future therapeutic for organ transplant recipients or graft-vs-host disease and is an approved therapeutic for psoriasis vulgaris, which is a T cell-mediated inflammatory disease. However, alefacept improves psoriasis in only ∼50{\%} of patients treated for 12 wk. We studied the immunologic effects of alefacept in a group of psoriasis patients during treatment. We found that T cells, especially CD8+ T cells, were rapidly decreased in the peripheral circulation. Decreases in circulating T cells were not associated with induced apoptosis. Unexpectedly, in addition to suppression of inflammatory genes, we found a marked induction of mRNAs for STAT1, IL-8, and monokine induced by IFN-γ during the first day of treatment in PBMC. We confirmed the agonistic effects of alefacept in PBMC in vitro, which were similar to CD3/CD28 ligation on T cells. These data establish that alefacept activates gene expression programs in leukocytes and suggest that its therapeutic action may be as a mixed agonist/antagonist. Furthermore, responding patients to alefacept treatment show unique patterns of gene modulation. Whereas alefacept down-regulated TCRs CD3D and CD2 in responders, nonresponders reveal a higher expression of T cell activation genes such as CD69 in pretreatment PBMC. These finding suggest a potential basis for categorizing responders vs nonresponders at an early time point in treatment or before treatment of a broad range of proinflammatory diseases. This study 1) establishes alefacept as a novel CD2 agonist molecule for induction of leukocyte activation genes (prior work proposed its mechanism as a CD2 antagonist) and 2) that differential activation of genes may categorize clinical responders to this agent, critical for cost-effective use of this drug.",
author = "Haider, {Asifa S.} and Lowes, {Michelle A.} and Humphrey Gardner and Raj Bandaru and Kamruz Darabi and Francesca Chamian and Toyoko Kikuchi and Patricia Gilleaudeau and Whalen, {Mary S.} and Irma Cardinale and Inna Novitskaya and Krueger, {James G.}",
year = "2007",
month = "6",
day = "1",
language = "English (US)",
volume = "178",
pages = "7442--7449",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "11",

}

TY - JOUR

T1 - Novel insight into the agonistic mechanism of alefacept in vivo

T2 - Differentially expressed genes may serve as biomarkers of response in psoriasis patients

AU - Haider, Asifa S.

AU - Lowes, Michelle A.

AU - Gardner, Humphrey

AU - Bandaru, Raj

AU - Darabi, Kamruz

AU - Chamian, Francesca

AU - Kikuchi, Toyoko

AU - Gilleaudeau, Patricia

AU - Whalen, Mary S.

AU - Cardinale, Irma

AU - Novitskaya, Inna

AU - Krueger, James G.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Alefacept is an LFA3-Ig fusion protein that binds to CD2 and is thought to inhibit T cell activation by antagonism of CD2 signaling or by lysis of CD2 + cells. Alefacept is potential future therapeutic for organ transplant recipients or graft-vs-host disease and is an approved therapeutic for psoriasis vulgaris, which is a T cell-mediated inflammatory disease. However, alefacept improves psoriasis in only ∼50% of patients treated for 12 wk. We studied the immunologic effects of alefacept in a group of psoriasis patients during treatment. We found that T cells, especially CD8+ T cells, were rapidly decreased in the peripheral circulation. Decreases in circulating T cells were not associated with induced apoptosis. Unexpectedly, in addition to suppression of inflammatory genes, we found a marked induction of mRNAs for STAT1, IL-8, and monokine induced by IFN-γ during the first day of treatment in PBMC. We confirmed the agonistic effects of alefacept in PBMC in vitro, which were similar to CD3/CD28 ligation on T cells. These data establish that alefacept activates gene expression programs in leukocytes and suggest that its therapeutic action may be as a mixed agonist/antagonist. Furthermore, responding patients to alefacept treatment show unique patterns of gene modulation. Whereas alefacept down-regulated TCRs CD3D and CD2 in responders, nonresponders reveal a higher expression of T cell activation genes such as CD69 in pretreatment PBMC. These finding suggest a potential basis for categorizing responders vs nonresponders at an early time point in treatment or before treatment of a broad range of proinflammatory diseases. This study 1) establishes alefacept as a novel CD2 agonist molecule for induction of leukocyte activation genes (prior work proposed its mechanism as a CD2 antagonist) and 2) that differential activation of genes may categorize clinical responders to this agent, critical for cost-effective use of this drug.

AB - Alefacept is an LFA3-Ig fusion protein that binds to CD2 and is thought to inhibit T cell activation by antagonism of CD2 signaling or by lysis of CD2 + cells. Alefacept is potential future therapeutic for organ transplant recipients or graft-vs-host disease and is an approved therapeutic for psoriasis vulgaris, which is a T cell-mediated inflammatory disease. However, alefacept improves psoriasis in only ∼50% of patients treated for 12 wk. We studied the immunologic effects of alefacept in a group of psoriasis patients during treatment. We found that T cells, especially CD8+ T cells, were rapidly decreased in the peripheral circulation. Decreases in circulating T cells were not associated with induced apoptosis. Unexpectedly, in addition to suppression of inflammatory genes, we found a marked induction of mRNAs for STAT1, IL-8, and monokine induced by IFN-γ during the first day of treatment in PBMC. We confirmed the agonistic effects of alefacept in PBMC in vitro, which were similar to CD3/CD28 ligation on T cells. These data establish that alefacept activates gene expression programs in leukocytes and suggest that its therapeutic action may be as a mixed agonist/antagonist. Furthermore, responding patients to alefacept treatment show unique patterns of gene modulation. Whereas alefacept down-regulated TCRs CD3D and CD2 in responders, nonresponders reveal a higher expression of T cell activation genes such as CD69 in pretreatment PBMC. These finding suggest a potential basis for categorizing responders vs nonresponders at an early time point in treatment or before treatment of a broad range of proinflammatory diseases. This study 1) establishes alefacept as a novel CD2 agonist molecule for induction of leukocyte activation genes (prior work proposed its mechanism as a CD2 antagonist) and 2) that differential activation of genes may categorize clinical responders to this agent, critical for cost-effective use of this drug.

UR - http://www.scopus.com/inward/record.url?scp=34249826335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249826335&partnerID=8YFLogxK

M3 - Article

VL - 178

SP - 7442

EP - 7449

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 11

ER -